[1]雷祥,崔红培,李漫丽,等.雷珠单抗联合全视网膜光凝治疗缺血型视网膜中央静脉阻塞的疗效观察[J].眼科新进展,2019,39(1):041-44.[doi:10.13389/j.cnki.rao.2019.0009]
　LEI Xiang,CUI Hong-Pei,LI Man-Li,et al.Ranibizumab combined with panrentinal photocoagulation for the treatment of ischemic central retinal vein occlusion[J].Recent Advances in Ophthalmology,2019,39(1):041-44.[doi:10.13389/j.cnki.rao.2019.0009]
点击复制

雷珠单抗联合全视网膜光凝治疗缺血型视网膜中央静脉阻塞的疗效观察/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
39卷
期数:
2019年1期
页码:
041-44
栏目:
应用研究
出版日期:
2019-01-05

文章信息/Info

Title:
Ranibizumab combined with panrentinal photocoagulation for the treatment of ischemic central retinal vein occlusion
作者:
雷祥; 崔红培; 李漫丽; 李翔; 武文忠; 栗占荣; 范珂
450003　河南省郑州市，河南省立眼科医院 河南省眼科研究所 河南省人民医院
Author(s):
LEI Xiang; CUI Hong-Pei; LI Man-Li; LI Xiang; WU Wen-Zhong; LI Zhan-Rong; FAN Ke
Henan Eye Hospital，Henan Eye Institute，Henan Province People’s Hospital，Zhengzhou 450003，Henan Province，China
关键词:
缺血型; 视网膜中央静脉阻塞; 全视网膜光凝; 雷珠单抗; 疗效
Keywords:
central retinal vein occlusion; ischemic type; ranibizumab; panretinal photocoagulation; curative effect
分类号:
R774
DOI:
10.13389/j.cnki.rao.2019.0009
文献标志码:
A
摘要:
目的　探讨雷珠单抗联合全视网膜光凝（panretinal photocoagulation，PRP）治疗缺血型视网膜中央静脉阻塞（central retinal vein occlusion，CRVO）的效果。方法　选取2014年6月至2016年6月我院收治的缺血型CRVO患者90例（90眼），采用随机数字表法分为观察组和对照组，每组各45例45眼，根据病程再将两组患者各分为两个亚组，A组病程≤3个月，B组病程>3个月，观察A、B组采用玻璃体内注射雷珠单抗（intravitreal injection of ranibizumab，IVR）+PRP治疗，对照A、B组采用单独PRP治疗，比较4组房水中血管内皮生长因子（vascular endothelial growth factor，VEGF）水平，记录IVR前、PRP时及PRP后1周、1个月、3个月最佳矫正视力（best corrected visual acuity，BCVA）、黄斑中心凹视网膜厚度（central macular thickness，CMT），并观察黄斑水肿复发率及不良反应。结果　观察A组和观察B组PRP时房水VEGF浓度较IVR前降低，且显著低于对照A组、对照B组，差异均有统计学意义（均为P＜0.05）；观察A组PRP时及PRP后1周、1个月、3个月BCVA均优于对照A组，观察B组优于对照B组（均为P＜0.05），且观察A组与观察B组、对照A组与对照B组比较，差异均有统计学意义（均为P＜0.05）；观察A组PRP后1周、1个月、3个月CMT均显著低于对照A组，观察B组低于对照B组（均为P＜0.05），但观察A组与观察B组、对照A组与对照B组各时间点比较，差异均无统计学意义（均为P＞0.05）；观察A组和对照A组均未出现黄斑水肿复发，观察B组、对照B组黄斑水肿复发率分别为6.25%、10.0%，4组比较差异无统计学意义（P＞0.05）；4组均未出现严重不良反应。结论　早期采用IVR联合PRP治疗缺血型CRVO效果确切，可显著改善视力水平。
Abstract:
Objective　To explore the effects of ranibizumab combined with panrentinal photocoagulation （PRP） in the treatment of ischemic central retinal vein occlusion （CRVO）.Methods　Totally 90 patients （90 eyes） with ischemic CRVO who were admitted to our hospital from June 2014 to June 2016 were enrolled in the study.They were divided into the observation group and the control group by random number table，45 patients （45 eyes） in each group.According to the course of the disease，patients in each group were divided into two subgroups，namely，the observation group A （the course ≤3 months） and B （the course >3 months）［all patients were treated by intravitreal injection of ranibizumab （IVR）+PRP］ and the control group A （the course ≤3 months） and B （the course >3 months)（all patients were treated by PRP alone）.The vascular endothelial growth factor （VEGF） in aqueous humor was compared among the 4 groups.The best corrected visual acuity （BCVA） and central macular thickness （CMT） were recorded before IVR，at PRP and at 1 week，1 month and 3 months after PRP.The recurrence rate of macular edema and adverse reactions during the follow-up period were statistically analyzed.Results　The VEGF levels in aqueous humor in the observation group A and B at PRP were significantly lower than those before injection of IVR and those in the control group A and B，with significant difference （all P<0.05）.The logMAR BCVA of the observation group A at PRP and at 1 week，1 month and 3 months after PRP was better than that of the control group A，and that of the observation group B groups was superior to that of the control group B，with significant differences between the observation group A and the observation group B or between the control group A and the control group B （all P<0.05）.The CMT of the observation group A at 1 week，1 month and 3 months after PRP was lower than that of the control group A，and that of the observation group B groups was smaller than that of the control group B，with significant difference （all P<0.05），but there was no significant difference between the observation group A and the observation group B or between the control group A and the control group B （both P>0.05）.No recurrence of macular edema was observed in the observation group A and the control group A.The recurrence rate of macular edema in the observation group B and the control group B were 6.25% and 10.0%，respectively，without significant difference among the 4 groups （P>0.05）.No serious adverse reactions were found in the 4 groups.Conclusion　Early application of IVR combined with PRP is effective in the treatment of ischemic CRVO，and the visual acuity can be improved significantly.

参考文献/References:

［1］　LARSEN M，WALDSTEIN S M，BOSCIA F，GERDING H，MONS J，TADAYONI R，et al.Individualized ranibizumab regimen driven by stabilization criteria for central retinal vein occlusion：twelve-month results of the CRYSTAL Study［J］.Ophthalmology，2016，123（5）：1101-1111.
［2］　SUN J K.Comparing anti-vascular endothelial growth factor therapies for central retinal vein occlusion［J］.JAMA Ophthalmol，2017，135（6）：649-650.
［3］　WINTERHALTER S，ECKERT A，VOM BROCKE G A，SCHN-EIDER A，POHLMANN D，PILGER D，et al.Real-life clinical data for dexamethasone and ranibizumab in the treatment of branch or central retinal vein occlusion over a period of six months［J］.Graefes Arch Clin Exp Ophthalmol，2018，265（6）：267-279.
［4］　ZHANG H R.Clinical and basic research on retinopathy［M］.Taiyuan:Shanxi Science and Technology Press，1999：89-91.
张惠蓉.视网膜病临床和基础研究［M］.太原：山西科学技术出版社，1999：89-91.
［5］　ZHAO J，LIU F Y，CHEN Y S.Levels of VEGF，IL-6 and Leptin in the aqueous humor of type 2 diabetic patients［J］.Rec Adv Ophthalmol，2008，28（4）：287-289.
赵军，刘方毅，陈永生.2型糖尿病患者房水中VEGF、IL-6、Leptin水平测定的临床意义［J］.眼科新进展，2008，28（4）：287-289.
［6］　BORMANN C，HEICHEL J，HAMMER U，HABERMANN A，HAM-MER T.Intravitreal anti-vascular endothelial growth factor for macular edema due to complex retinal arterial macroaneurysms［J］.Case Rep Ophthalmol，2017，8（1）：137-143.
［7］　ZHOU J，WANG H B，WANG W T.Efficacy of intravitreal injection of ranibizumab for retinal vein occlusion［J］.Rec Adv Ophthalmol，2016，36（1）：70-73.
周洁，王宏彬，王文亭.雷珠单抗治疗视网膜静脉阻塞的临床研究［J］.眼科新进展，2016，36（1）：70-73.
［8］　ZHAO C，WANG F，CHEN L，SHI Y H，YE S，XU C Q，et al.Effect of ranibizumab on serous pigment epithelial detachments associated with wet age-related macular degeneration［J］.Chin J Ocul Fund Dis，2015，31（1）：27-30.
赵莼，王方，陈磊，施岳辉，叶盛，徐璨卿，等.玻璃体腔注射雷珠单抗治疗渗出型老年性黄斑变性伴浆液性视网膜色素上皮脱离的疗效观察［J］.中华眼底病杂志，2015，31（1）：27-30.
［9］　LIAN H Y，SONG Y P，DING Q.Baseline characteristics and visual outcomes after two years follow-up of exudative age-related macular；degeneration patients treated with ranibizumb［J］.Chin J Ocul Fund Dis，2017，33（1）：40-43.
连海燕，宋艳萍，丁琴.玻璃体腔注射雷珠单抗治疗渗出型老年性黄斑变性患眼随访2年终末视力与基线特征相关性观察［J］.中华眼底病杂志，2017，33（1）：40-43.
［10］　ZHANG J，CAI X J，CHEN X M，ZHEN T，GUO B C，HAN F F，et al.A prospective randomized clinical trial on intravitreous injection of Conbercept combined with laser photocoagulation for macular edema secondary to branch retinal vein occlusion［J］.Chin J Ocul Fund Dis，2015，31（1）：22-26.
张菁，蔡小军，陈晓敏，郑恬，郭别川，韩芳芳，等.玻璃体腔注射康柏西普联合视网膜激光光凝治疗视网膜分支静脉阻塞继发黄斑水肿疗效观察［J］.中华眼底病杂志，2015，31（1）：22-26.
［11］　LI S Y，GAO R Y，CHEN H.Effects of ranibizumab （Lucentis） intravitreal injec- tion combined with retinal argon laser photocoagula- tion on macular edema secondary to different period of branch retinal vein occlusion［J］.Rec Adv Ophthalmol，2016，36（12）：1161-1164.
李仕永，高瑞莹，陈晖.雷珠单抗联合氩激光视网膜光凝治疗不同时期的视网膜分支静脉阻塞所致黄斑水肿的疗效［J］.眼科新进展，2016，36（12）：1161-1164.

相似文献/References:

[1]杨于力 刘勇 阴正勤 王一.眼部缺血综合征患者视网膜电图明视负向反应和震荡电位的变化特点[J].眼科新进展,2012,32(4):000.
[2]魏光杰 何佃菊.532nm绿激光全视网膜光凝术联合中药治疗视网膜中央静脉阻塞的疗效分析[J].眼科新进展,2013,33(10):000.
[3]刘李平 宋徽 肖云 曹小鹏 白润 陈珍.玻璃体注射雷珠单抗治疗缺血型视网膜中央静脉阻塞的临床观察[J].眼科新进展,2013,33(11):000.
[4]董子奕,彭清华,李建超,等. 兔视网膜中央静脉阻塞模型中小胶质细胞CD40和铁蛋白的表达[J].眼科新进展,2015,35(2):116.[doi:10.13389/j.cnki.rao.2015.0031]
　DONG Zi-Yi,PENG Qing-Hua,LI Jian-Chao,et al. Expression of microglia cells CD40 and ferritin in rabbit model of central retinal vein occlusion[J].Recent Advances in Ophthalmology,2015,35(1):116.[doi:10.13389/j.cnki.rao.2015.0031]
[5]胡一骏,李冬莉,李国栋,等.视网膜静脉阻塞的危险因素分析[J].眼科新进展,2017,37(6):544.[doi:10.13389/j.cnki.rao.2017.0137]
　HU Yi-Jun,LI Dong-Li,LI Guo-Dong,et al.Risk factors associated with retinal vein occlusion[J].Recent Advances in Ophthalmology,2017,37(1):544.[doi:10.13389/j.cnki.rao.2017.0137]
[6]王梅子,封康,陆遥,等.贝伐单抗治疗视网膜中央静脉阻塞（CRVO）继发黄斑水肿的短期疗效及影响因素分析[J].眼科新进展,2018,38(12):1176.[doi:10.13389/j.cnki.rao.2018.0278]
　WANG Mei-Zi,FENG Kang,LU Yao,et al.Analysis of short-term outcomes and factors for intravitreal bevacizumab in the treatment of macular edema secondary to central retinal vein occlusion[J].Recent Advances in Ophthalmology,2018,38(1):1176.[doi:10.13389/j.cnki.rao.2018.0278]
[7]陈莲,王延辉,杨帆,等.视网膜中央静脉阻塞与阻塞性睡眠呼吸暂停综合征的相关性[J].眼科新进展,2019,39(2):183.[doi:10.13389/j.cnki.rao.2019.0042]
　CHEN Lian,WANG Yan-Hui,YANG Fan,et al.Relationship between central retinal vein occlusion and obstructive sleep apnea syndrome[J].Recent Advances in Ophthalmology,2019,39(1):183.[doi:10.13389/j.cnki.rao.2019.0042]
[8]赵通,张利,尹玥,等.玻璃体内注射康柏西普联合后筋膜囊注射曲安奈德对视网膜中央静脉阻塞继发顽固性黄斑水肿患者的治疗效果[J].眼科新进展,2020,40(4):369.[doi:10.13389/j.cnki.rao.2020.0085]
　ZHAO Tong,ZHANG Li,YIN Yue,et al.Efficacy of intravitreal injection of Conbercept combined with posterior fascial capsular injection of Triamcinolone Acetonide for treatment of macular edema secondary to central retinal vein occlusion[J].Recent Advances in Ophthalmology,2020,40(1):369.[doi:10.13389/j.cnki.rao.2020.0085]
[9]董立红,张大传.不同时机视网膜激光光凝辅助康柏西普治疗视网膜中央静脉阻塞继发黄斑水肿的疗效分析[J].眼科新进展,2022,42(7):546.[doi:10.13389/j.cnki.rao.2022.0112]
　DONG Lihong,ZHANG Dachuan.Clinical effect of retinal photocoagulation and conbercept in the treatment of macular edema secondary to central retinal vein occlusion at different times[J].Recent Advances in Ophthalmology,2022,42(1):546.[doi:10.13389/j.cnki.rao.2022.0112]
[10]邢振,王淑娜,孙艳,等.雷珠单抗治疗缺血型和非缺血型视网膜分支静脉阻塞继发黄斑水肿患者视网膜体积变化的对比研究[J].眼科新进展,2024,44(3):217.[doi:10.13389/j.cnki.rao.2024.0043]
　XING Zhen,WANG Shuna,SUN Yan,et al.Comparative study of retinal volume changes in ischemic and non-ischemic macular edema secondary to branch retinal vein occlusion treated with ranibizumab[J].Recent Advances in Ophthalmology,2024,44(1):217.[doi:10.13389/j.cnki.rao.2024.0043]

备注/Memo

备注/Memo:
国家自然科学基金（编号：81600775）
更新日期/Last Update: 2019-01-04